Navigation Links
First genetically engineered malaria vaccine to enter human trials

Walter and Eliza Hall Institute scientists have created a weakened strain of the malaria parasite that will be used as a live vaccine against the disease. The vaccine, developed in collaboration with researchers from the US, Japan and Canada, will be trialled in humans from early next year.

Malaria kills more than one million people each year and destroys through premature death and disability the equivalent of at least 35 million years of healthy, productive human life every year.

Professor Alan Cowman, head of the institute's Infection and Immunity division, said in developing the vaccine the research team had deleted two key genes in the Plasmodium falciparum parasite which causes the form of malaria most deadly to humans. By removing the genes the malaria parasite is halted during its liver infection phase, preventing it from spreading to the blood stream where it can cause severe disease and death.

Their success in genetically modifying the parasite and thereby preventing its invasion of red blood cells is published in the current issue of the Proceedings of the National Academy of Sciences USA.

Professor Cowman said similar vaccines had been tested in mice and offered 100 per cent protection against malaria infection. He said it was hoped the vaccine would produce similar results in humans. "Although two genes have been deleted the parasite is still alive and able to stimulate the body's protective immune system to recognize and destroy incoming mosquito-transmitted deadly parasites," Professor Cowman said.

This approach to vaccine development using a weakened form of the whole organism that causes a particular disease has proven successful in eradicating smallpox and controlling diseases such as flu and polio.

Professor Cowman said the research team, which includes Dr Matthew O'Neill and Dr Alex Maier from the institute as well as scientists from the Seattle Biomedical Research Institute, the Walter Reed Army Institute for Research and the University of Maryland, had used knowledge from several decades ago when scientists proved that irradiated malaria parasites provide protection against subsequent malaria infection in animal models and humans in developing the vaccine.

"Although vaccines are under development that use whole malaria parasites weakened by irradiation to protect against infection, their safety and effectiveness rely on a precise irradiation dose and trial results have been variable," Professor Cowman said. "We believe that our genetically attenuated parasite approach provides a safe and reproducible way of developing a whole organism malaria vaccine."

Professor Cowman said it was unlikely the weakened parasites used in the vaccine would regain their potency as the genes had been deleted from the genome and could not be recreated by the parasite. "In addition, the 'one-two punch' approach of deleting two essential genes make it extremely unlikely that the attenuated parasite vaccine could restore its capacity to multiply and lead to disease," he said.

The human trials of the vaccine will take place at the Walter Reed Army Institute of Research in Maryland, US. The genetically attenuated parasites to be used in the trial are being manufactured at the Walter and Eliza Hall Institute, which has the only facility worldwide capable of producing genetically-altered malaria parasites that comply with the good manufacturing practice guidelines required for human clinical trials.


Contact: Penny Fannin
Walter and Eliza Hall Institute

Related biology technology :

1. First U.K. Stem Cell Awareness Rally to Take Place in Manchester, England on August 9th, 2009
2. RadMD First to Offer CME-Certified Education and Training For Medical Imaging in Clinical Trials
3. GreenHouse Debuts the World's First E-Fuel MicroFuelerTM in Los Angeles
4. FDA Grants First Authorization of a Commercial 2009 H1N1 Flu Test for use During Pandemic Flu Emergency to Quest Diagnostics Focus Diagnostics Business
5. Surgeon Performs First Single Incision Peri-Umbilical Laparoscopic Surgery in the State of Missouri
6. OpenQ Posts a 200% Revenue Growth in the First Half of 2009
7. Essilor : First Half 2009 Revenue
8. Sumavel(TM) DosePro(TM) (sumatriptan injection) Approved by FDA for Acute Migraine and Cluster Headache: First Product Featuring Novel DosePro Needle-Free Delivery System
9. China Biologic Products Hosts its First Forum for Strategy and Development
10. First Catalog Cancer Biochip for Sequence Capture Now Available from febit
11. Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
Post Your Comments:
Related Image:
First genetically engineered malaria vaccine to enter human trials
(Date:6/27/2016)... DIEGO , June 27, 2016  Sequenom, Inc. ... committed to enabling healthier lives through the development of ... Court of the United States ... courts that the claims of Sequenom,s U.S. Patent No. ... patent eligibility criteria established by the Supreme Court,s Mayo ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/27/2016)... June 27, 2016   Ginkgo Bioworks , a ... engineering, was today awarded as one of the ... the world,s most innovative companies. Ginkgo Bioworks is ... the real world in the nutrition, health and ... directly with customers including Fortune 500 companies to ...
Breaking Biology Technology:
(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
Breaking Biology News(10 mins):